BioWorld

Oct. 22, 2004

View Archived Issues

After Flu Vaccine Mess, Chiron's Q3 Earnings 'Almost Irrelevant'

Chiron Corp. released its third-quarter earnings Wednesday, and while those figures were better than expected, the Fluvirin disaster has faded their importance. (BioWorld Today) Read More

MedImmune Beats Estimates, Begins CAIV-T Phase III Study

Read More

Tularik Buyout Slows Amgen; Still Beats Analysts' Estimates

Read More

Positive Phase III CTLA4-Ig Data Bump Repligen's Stock

Read More

Other News To Note

Read More